Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting

Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

Aileron Therapeutics Reports Third Quarter 2018 Financial Results

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018

Aileron Announces Poster Presentations at Two Scientific Conferences in November

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

Aileron Therapeutics Reports Second Quarter 2018 Financial Results